|
ÀÎÅÚ¸®Àü½ºÄÚ¸®¾Æ |
[¹Ì±¹°è Á¦¾àȸ»ç] CTA
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
03.08 |
|
|
(ÁÖ)ºê·£µå¹Ì |
±×·ì»ç Á¦¾àÀǾà ÀÓ»ó CRA
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
10.03 |
|
|
ÄÚ¸®¾Æºê·¹ÀÎ ((ÁÖ)¿¡ÀÌÄ¡¾ËÇãºê) |
Associate/Director, Clinical Operations, Medical Device
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
10.23 |
|
|
(ÁÖ)ÀâÀ§µå |
(¿Ü±¹°è/Á¦¾à) Àӻ󿬱¸ / CTA/ CRO ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
11.30 |
|
|
(ÁÖ)ÀâÀ§µå |
(¿Ü±¹°è/Á¦¾à) ÀÓ»ó ¿¬±¸ »ç¹« / CTA ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
11.19 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
Clinical Research Science °úÂ÷Àå±Þ/±¹³»À¯¸íÁ¦¾àȸ»ç
¼¿ï ÀüÁö¿ª | ´ëÇпø(¼®»ç) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
3³â¡è |
ä¿ë½Ã |
10.15 |
|
|
(ÁÖ)¶ó¿Â¼Ä¡ |
±×·ìÁ¦¾à»ç - ÀǾàÇ°¾ÈÀü¼º(PharmD / Pharmacovigilance)
°æ±â ÀüÁö¿ª | ´ëÇпø(¼®»ç) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
4³â¡è |
ä¿ë½Ã |
07.21 |
|
|
(ÁÖ)¸®¿ÂÆÄÆ®³Ê½º |
±Û·Î¹ú Á¦¾à»ç ÀÓ»ó Manager(MSL°æ·Â º¸À¯ÀÚ) ¹× 5³â ÀÌ»ó L
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
12.03 |
|
|
ÅÛÇÁ½ºÅÜÄÚ¸®¾ÆÁÖ½Äȸ»ç |
[¿Ü±¹°è ÀÇ·á±â±â ±â¾÷] CRA
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
02.27 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
CRA(Global trial: ±¹³» ÁøÇà ¹× ÇØ¿Ü °ü¸®)/±¹³»À¯¸íÁ¦¾àȸ
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
3³â¡è |
ä¿ë½Ã |
10.15 |
|
|
(ÁÖ)ÀâÀ§µå |
(¿Ü±¹°è/ÀÇ·á/270¸¸ÀÌ»ó/2´Þ) ÀÇÇÐÁö½Ä µ¥ÀÌÅÍ ÀÚ·áÁ¤¸®,°Ë
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
10.23 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
ÀÓ»óÆÀÆÀÀå/±¹³»Áß°ßÁ¦¾àȸ»ç
¼¿ï ¿ë»ê±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
7³â¡è |
ä¿ë½Ã |
01.25 |
|
|
ÅÛÇÁ½ºÅÜÄÚ¸®¾ÆÁÖ½Äȸ»ç |
±Û·Î¹ú ½Å¾à°³¹ß»ç CRA
¼¿ï ±¸·Î±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
12.26 |
|
|
³ª¿ìÆÊÄÁ¼³Æà |
¿ÜÀÚ°è-PV Manager
¼¿ï ÀüÁö¿ª | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
11.26 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
ÀÓ»ó´ã´çÀÚ(7³â ÀÌ»ó °æ·ÂÀÇ ºÐ)/±¹³»À¯¸íÁ¦¾àȸ»ç
¼¿ï ¿ë»ê±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
7³â¡è |
ä¿ë½Ã |
03.12 |
|